For the quickest response, Please Email Us

BHRT Risks

BHRT Risks in NYC: What the Evidence Shows, Which Women Face Which Risks, and Where the Research Runs Out

Smiling midlife woman with curly hair in a blue shirt outdoors in a garden

Few questions about hormone therapy are asked more often, or answered less evenly, than whether it is safe. Some women have been told it is dangerous and should be avoided. Others have been told, usually by someone selling it, that bioidentical hormones are natural and therefore gentle. Neither statement holds up. The honest answer is that the risks are real, they are not the same for every woman, and they depend on factors that can be identified before treatment starts: age, timing, the type of hormone, how it is taken, the dose and the woman's own history.

Women in New York who search for BHRT risks are usually weighing a specific decision. They are in their forties and sleeping badly, or past menopause with hot flashes that will not stop, and a clinic has offered them treatment. What they want to know is what could go wrong, how likely it is, whether it can be caught early and whether the person in front of them will tell them the truth.

This article puts the risks first. It explains what large studies showed and how the picture changed, how breast cancer, clot, stroke, uterine and gallbladder risks work, how the route and the product change them, who should not take hormones at all, where the evidence runs out and what monitoring looks like. The case for treatment is real, and this is the more cautious side of the same decision. It reflects the perspective of Dr. Bissoon, a physician at Liondale Medical in Manhattan.

Why the Word Bioidentical Does Not Settle the Safety Question

A bioidentical hormone has the same molecular structure as a hormone the human body makes. Estradiol, the main estrogen produced by the ovaries, is a bioidentical estrogen when made in a laboratory with its exact structure. Micronized progesterone is a bioidentical form of progesterone, and testosterone, as prescribed, is also structurally identical to what the body produces.

That definition has two consequences that surprise people. The first is that bioidentical hormones are not a niche or alternative product. Several are approved by the FDA and are sold as patches, gels, tablets, rings and capsules, made by pharmaceutical companies and tested for dose consistency. The second is that structure alone does not make something safer. Estradiol is estradiol whether it arrives in a branded patch or a compounded cream, and the risks that come with estrogen come with it.

Some older products used estrogens derived from horses or progestins that are chemically different from natural progesterone. These are not bioidentical, and they have a different record. The distinction is real, but it is one factor among several, and it does not justify the claim that everything bioidentical is better.

Approved and Compounded Products Carry Different Unknowns

Products that are FDA approved go through review of their manufacturing, their dosing and their safety and efficacy data. A patch labeled with a given dose delivers about that dose, and the label carries standard warnings.

Compounded products, prepared by a pharmacy to a prescription, can be useful when a patient needs a dose, an ingredient or a form that is not commercially available, or when an allergy rules out an ingredient in a standard product. But they are not reviewed by the FDA for safety, effectiveness or consistency in the same way, and the claims sometimes made for them, such as being safer or more natural than approved products, are not supported by evidence. Professional societies generally advise using approved products when they meet the patient's needs.

A patient should always be able to find out which kind of product they are receiving, who makes it and how it is dosed. That question alone is revealing.

What the Risks Are Weighed Against

Risk only means something next to benefit, and the benefits fall into tiers according to the strength of the evidence.

The strongest indication is hot flashes and night sweats. Estrogen is the most effective treatment available for vasomotor symptoms, reducing both frequency and severity in many women, often within weeks. By reducing night sweats and sometimes through other mechanisms, hormone therapy often improves sleep. Vaginal dryness, discomfort with intercourse and urinary symptoms related to low estrogen respond well to estrogen, including low dose vaginal products that act locally with minimal absorption into the blood. Estrogen also reduces bone loss and fracture risk and is approved for preventing osteoporosis, although other medications are generally preferred when bone protection is the only goal.

Beyond those, the picture is more mixed. Some studies suggest that estrogen can help depressive symptoms in perimenopausal women, particularly when delivered transdermally, but the evidence is less consistent after menopause, and hormone therapy is not a first line treatment for clinical depression. Many women report better focus and memory, and some of that reflects better sleep and fewer hot flashes. Large studies have not shown that hormone therapy reliably prevents cognitive decline or dementia, and it is not approved for that purpose. Some headlines have suggested that starting early might protect the brain, and the research on hormone therapy and Alzheimer's is an area of active study, not a settled indication. Hormone therapy is also not prescribed to prevent heart disease.

How One Early Trial Reshaped What Women Were Told

In the early 2000s, a large trial reported that combined estrogen and progestin therapy increased the risk of breast cancer, blood clots, stroke and heart disease in the women studied, and prescribing fell sharply. Later analysis found that the average age of participants was well past menopause, and that the picture looked different in women who started therapy closer to menopause, under sixty or within ten years of their final period. Risk and benefit appear to depend on age, timing, dose, type of estrogen and route of delivery, as well as the individual woman.

That reanalysis is sometimes described as proof that hormones are safe, which overstates it. It supports a more careful claim: for healthy women under sixty, near menopause, with bothersome symptoms and no contraindications, the balance of benefit and risk is generally favorable, and for older women or those starting much later, it is less so. Professional societies have reached broadly similar conclusions.

The practical lesson is that blanket statements in either direction, that hormones are dangerous or that they are harmless, are not accurate. The decision is individual.

Breast Cancer: A Small Absolute Risk With a Real Signal

Long term use of combined estrogen and progestogen therapy is associated with a small increase in breast cancer risk, which appears to rise with duration. Estrogen alone, used by women who have had a hysterectomy, has shown a different pattern in studies. Absolute risks are small compared with other factors such as age, alcohol and weight, but they are real and belong in the discussion. Mammography continues on the usual schedule for age and risk, and women with strong family histories need particularly careful assessment before starting.

Blood Clots and Stroke: Why the Route Matters

Oral estrogen is associated with an increased risk of blood clots, because it passes through the liver and affects clotting factors. Transdermal estrogen, in patches or gels, appears to carry a lower clot risk. Stroke risk may be modestly increased with some regimens.

The route explains much of the difference. Patches and gels deliver estradiol through the skin, bypassing the first pass through the liver, and are generally associated with lower clot risk than oral estrogen. They provide steady levels and allow dose adjustment, though some people have skin irritation and patches can fall off. Oral tablets are convenient and well studied but are associated with higher clotting and gallbladder risk and affect liver proteins.

Because vascular risk matters here, a careful assessment looks beyond a standard cholesterol panel, for example at particle measures such as ApoB, which can show risk that ordinary lab work misses.

The Uterine Lining and Why a Progestogen Is Added

Estrogen without a progestogen in a woman who still has a uterus increases the risk of cancer of the uterine lining, which is why a progestogen is added to protect it. Progesterone is usually taken as a capsule at night, where its calming effect can help sleep. Estrogen alone is the pattern studied in women who have had a hysterectomy, and that difference changes the risk discussion. Any new bleeding after menopause should be evaluated promptly.

Gallbladder Disease, Side Effects and the Smaller Risks

Oral estrogen is associated with higher rates of gallbladder problems. Breast tenderness, bloating, spotting and mood changes are common early on and often settle with dose or product adjustments.

None of this means that hormone therapy should be avoided. It means that it should be prescribed by someone who explains the risks, individualizes the choice and monitors the patient.

Pellets, Vaginal Products and the Dose You Cannot Adjust

Vaginal estrogen, in creams, tablets or rings, treats local symptoms with very low systemic absorption and is useful for women who cannot or do not wish to take systemic hormones. Pellets are a different matter. They are small implants placed under the skin that release hormone for months. They are convenient, but the dose cannot be adjusted once placed, levels can be higher than intended in some patients and they are not FDA approved in the form usually used for women's menopausal therapy. Many professional societies advise caution. For men's testosterone, the comparison of pellets versus shots shows the same trade-offs between convenience and flexibility.

A clinic should explain why it recommends one method for you, and what the alternatives would be.

Testosterone for Women: Off Label and Thinly Studied

Testosterone is sometimes added for low sexual desire that causes distress in postmenopausal women, and in that setting it has the best evidence. It is not approved in the United States as a product for women, so it is prescribed off label, usually in low doses designed to keep levels within the female range. Side effects such as acne, hair growth and changes in cholesterol are possible, and monitoring is needed. It is not a general energy or mood treatment, and it is not a substitute for addressing the underlying causes of low desire.

Who Should Not Take Hormones at All

Certain conditions are generally contraindications or call for specialist input. They include a history of breast cancer or other hormone sensitive cancers, unexplained vaginal bleeding, a history of blood clots or certain clotting disorders, a history of stroke or heart attack, active liver disease and pregnancy. Some women with migraine with aura, uncontrolled high blood pressure or strong family histories need particularly careful assessment.

Women who start many years after menopause, or past sixty, usually require a different risk discussion, and sometimes a different recommendation. This is part of why the question of when to begin is so central to the decision.

Perimenopause Changes the Risk Questions

Women in perimenopause are often the most symptomatic and the least well served. Hormone levels swing, cycles are unpredictable, pregnancy remains possible and symptoms such as anxiety, sleep disruption, migraines and heavy bleeding may be prominent.

Treatment is more individualized than in postmenopause. Options include low dose hormonal contraceptives, a progestogen to regulate cycles, a hormonal intrauterine device, transdermal estrogen in appropriate doses and non hormonal approaches. A clinic that treats perimenopause with the same protocol it uses for postmenopause is not paying attention to the difference. Hormone therapy for menopausal symptoms is not contraception, and that needs saying plainly.

Chasing Hormone Numbers Is Its Own Risk

Some practices treat hormone therapy as a matter of achieving target levels on a lab report, and adjust doses until the numbers reach a preset range. The appeal is obvious, since numbers feel objective. The difficulty is that the relationship between a blood level and symptom relief is imperfect, and that levels from different delivery methods behave differently.

Most guidelines recommend a different approach for menopausal symptoms: start with the lowest dose likely to be effective, assess response on symptoms, adjust gradually and reassess periodically. Laboratory measurements have a role, especially for certain delivery methods and for monitoring, but treatment is guided by the patient's response and safety, not by a number alone. Hormone levels fluctuate widely in perimenopause, so a single value can mislead. Saliva and some at home hormone tests are not considered reliable for guiding dosing, and a clinic that relies on them should be asked why.

A practice that can explain why it is measuring what it measures and what it will do with the result is practicing medicine. One that promises to optimize your levels without describing what that means deserves questions. How ordinary testing differs from a more detailed set is covered by the discussion of precision diagnostics.

What the Research Does Not Yet Tell Us

Honest practice includes admitting the gaps. There are few long, head to head trials comparing different delivery methods and doses for outcomes that matter, such as breast cancer or dementia. Most women in the large trials were white and many were older at the start, so the data apply imperfectly to a diverse city like New York. Evidence on compounded products is thin, and evidence on off label uses such as testosterone in women is limited to specific indications.

None of this is a reason to withhold treatment from women who clearly benefit. It is a reason for caution about claims that go beyond the data, and for a clinic that updates its approach as the evidence changes.

Monitoring That Catches Problems Early

Starting treatment is the beginning of a relationship, not the end of one. A reasonable schedule includes a follow up within a few months to assess symptoms and side effects, adjustment of the dose or product, and then regular reviews, usually annually, to reconsider whether treatment is still needed and at what dose.

Routine care continues alongside: mammography on the usual schedule for age and risk, cervical screening, blood pressure, lipids and glucose, and bone density where appropriate. Any new bleeding after menopause should be evaluated promptly. If symptoms resolve, the discussion includes whether to continue, taper or stop, and there is no fixed time limit that applies to everyone. The decision depends on the woman's symptoms, risks and preferences.

A practice that sees patients once and then refills prescriptions without review is missing the point. The process behind a lab result matters as much as the result, which is why it helps to understand how a blood sample travels from draw to report.

Weighing Risk Against Relief

Hormone therapy is neither a miracle nor a menace. For the right woman, at the right time, with a clear plan and appropriate monitoring, it can restore sleep, relieve symptoms and improve quality of life, with risks that are generally small and manageable. For the wrong woman, or in the wrong hands, it can be unnecessary or unsafe.

The way to find out which describes you is not to read a testimonial but to have a thorough evaluation with someone who will tell you the truth, including that you may not need it, and who will explain how each risk above applies to your history. Many women find it easier to weigh these trade-offs within a broader plan of menopause care. If you want that conversation, a consultation with a physician is a reasonable place to begin. Bring a list of your symptoms, any lab results, your medications and your questions, and expect a plan that fits you rather than a product.

Frequently Asked Questions

Is BHRT safe?

Safety depends on the type of hormone, the dose, how it is taken, the woman's age and time since menopause, and her own history. For healthy women under sixty, near menopause, with bothersome symptoms and no contraindications, the balance is generally favorable, and for others it is less so.

Does BHRT increase the risk of breast cancer?

Long-term use of combined estrogen and progestogen therapy is associated with a small increase in breast cancer risk that appears to rise with duration. Estrogen alone, used by women who have had a hysterectomy, has shown a different pattern, and absolute risks are small compared with factors such as age, alcohol and weight.

Is oral or transdermal estrogen safer for blood clots?

Oral estrogen is associated with a higher risk of blood clots because it passes through the liver and affects clotting factors. Transdermal estrogen, in patches or gels, appears to carry a lower clot risk.

Is compounded BHRT riskier than approved hormones?

There is no evidence that it is safer. Compounded products are not reviewed by the FDA in the same way, so dose consistency and quality can vary. Professional societies generally favor approved products when they meet the patient's needs.

Who should not take hormone therapy?

Women with a history of breast or other hormone-sensitive cancer, unexplained vaginal bleeding, blood clots, stroke, heart attack or active liver disease generally should not, and others need careful assessment. A physician can review your history.

Do the risks change with age at starting?

Yes. The balance of benefit and risk appears more favorable in women who start under sixty or within ten years of their final period, and women who start many years after menopause usually need a different risk discussion.

How are the risks monitored?

Typically with a follow-up within a few months of starting, dose or product adjustments, and regular reviews, usually annually, alongside routine mammography, blood pressure, lipids, glucose and bone density where appropriate. Any new bleeding after menopause should be evaluated promptly.

This page was written and medically reviewed by Lionel Bissoon, D.O., founder of Liondale Medical. Dr. Bissoon is a board-certified osteopathic physician specializing in anti-aging and concierge medicine on the Upper West Side of Manhattan.

This content is for educational purposes only and does not constitute medical advice. Individual results may vary. Consult a qualified physician before beginning any new treatment.

You Might Also Enjoy...

Opens in a new window.
Opens a PDF document.